Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology.

ABSTRACT:

Introduction

Soluble amyloid beta (Aβ) oligomers have been suggested as initiating Aβ related neuropathologic change in Alzheimer's disease (AD) but their quantitative distribution and chronological sequence within the AD continuum remain unclear.

Methods

A total of 526 participants in early clinical stages of AD and controls from a longitudinal cohort were neurobiologically classified for amyloid and tau pathology applying the AT(N) system. Aβ and tau oligomers in the quantified cerebrospinal fluid (CSF) were measured using surface-based fluorescence intensity distribution analysis (sFIDA) technology.

Results

Across groups, highest Aβ oligomer levels were found in A+ with subjective cognitive decline and mild cognitive impairment. Aβ oligomers were significantly high

SUBMITTER: Blomeke L 

PROVIDER: S-EPMC11044868 | biostudies-literature | 2024 Apr-Jun

REPOSITORIES: biostudies-literature